Vaxil Bio Ltd (TSE:VXL)
:VXL
Top Page
Vaxil Bio
(VXL)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.13
▼(-3.85% Downside)
Action:ReiteratedDate:01/09/26
The score is primarily weighed down by weak financial performance (no revenue, ongoing losses and cash burn) despite some improvement in loss and burn trends, and by bearish technicals with price below key moving averages and negative MACD. Valuation provides limited support because the negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
Low Leverage / Positive Equity
Very low debt and positive equity materially reduce solvency risk and preserve strategic optionality. Over a 2–6 month horizon this balance-sheet strength supports continued R&D investment or partnership negotiations without immediate pressure to take restrictive financing, improving survival odds.
Negative Factors
No Reported Revenue
Zero reported revenue indicates the business has not validated a commercial model; long-term viability depends on successful development or licensing. Over 2–6 months this maintains high execution and commercialization risk and keeps the company reliant on future clinical or partnership milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Positive Equity
Very low debt and positive equity materially reduce solvency risk and preserve strategic optionality. Over a 2–6 month horizon this balance-sheet strength supports continued R&D investment or partnership negotiations without immediate pressure to take restrictive financing, improving survival odds.
Read all positive factors
Vaxil Bio (VXL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$589.63K
Dividend YieldN/A
Average Volume (3M)1.45K
Price to Earnings (P/E)―
Beta (1Y)-0.65
Revenue GrowthN/A
EPS Growth46.32%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)39.22
Price to Sales (P/S)0.00
P/FCF Ratio-117.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaxil Bio Business Overview & Revenue Model
Company Description
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial f...
How the Company Makes Money
Vaxil Bio generates revenue primarily through the development and commercialization of its immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and potential milestone payments associated with...
Vaxil Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -2.00K | -25.00K | -57.00K |
| EBITDA | -189.00K | -178.00K | -252.00K | -582.00K | -961.00K | -1.29M |
| Net Income | -99.00K | -178.00K | -254.00 | -584.00K | -986.00K | -1.36M |
Balance Sheet | ||||||
| Total Assets | 697.00K | 733.00K | 976.00K | 1.54M | 2.29M | 1.66M |
| Cash, Cash Equivalents and Short-Term Investments | 347.00K | 714.00K | 938.00K | 1.51M | 2.24M | 1.51M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.00K |
| Total Liabilities | 6.00K | 17.00K | 85.00K | 405.00K | 585.00K | 857.00K |
| Stockholders Equity | 691.00K | 716.00K | 891.00K | 1.14M | 1.70M | 804.00K |
Cash Flow | ||||||
| Free Cash Flow | -157.08K | -240.00K | -561.00K | -734.00K | -1.08M | -1.10M |
| Operating Cash Flow | -157.08K | -240.00K | -561.00K | -734.00K | -1.08M | -1.10M |
| Investing Cash Flow | 0.00 | -250.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 1.81M | 2.56M |
Vaxil Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$6.00M | -0.15 | 123.88% | ― | ― | 90.81% | |
46 Neutral | C$40.89M | -0.56 | -205.87% | ― | ― | 62.01% | |
45 Neutral | C$29.83M | -6.55 | ― | ― | ― | 72.92% | |
43 Neutral | C$589.63K | -6.34 | -10.30% | ― | ― | 46.32% | |
42 Neutral | C$42.61M | -4.40 | -103.51% | ― | ― | 54.74% | |
| ― | C$1.89M | -1.60 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:VXL
Vaxil Bio
0.15
-0.10
-40.80%
TSE:APS
Aptose Biosciences
2.35
-1.50
-38.96%
TSE:MDNA
Medicenna Therapeutics Corp
0.62
-0.31
-33.33%
TSE:BCT
BriaCell Therapeutics
5.64
-49.26
-89.73%
TSE:BIOV
BioVaxys Technology
0.07
-0.39
-85.56%
TSE:DTC
Defence Therapeutics
0.52
-0.38
-42.22%
Vaxil Bio Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Vaxil Bio Completes Private Placement and Updates Board
Neutral
Dec 4, 2025
Vaxil Bio Ltd. has completed a non-brokered private placement, raising $140,000, which will be used to explore strategic options beyond the healthcare sector. The company has also announced changes to its board of directors, with the resignation o...
Business Operations and StrategyPrivate Placements and Financing
Vaxil Bio Revises Private Placement Terms to Raise $350,000
Neutral
Nov 24, 2025
Vaxil Bio Ltd. has announced a revision to the terms of its previously announced offering, now planning a non-brokered private placement to raise up to $350,000 through the sale of 3,111,111 units. Each unit includes one common share and one share...
Business Operations and StrategyPrivate Placements and Financing
Vaxil Bio Announces $350,000 Private Placement to Support Corporate Growth
Neutral
Oct 29, 2025
Vaxil Bio Ltd. has announced a non-brokered private placement to raise up to $350,000 through the issuance of 2,456,140 units, each comprising one common share and one share purchase warrant. The proceeds will be used for general corporate purpose...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.